What Is the Value of Three-Parent IVF?

Area of Science:

• Reproductive Medicine
• Bioethics
• Genetics

Background:

• Institute of Medicine (IOM) report on three-parent in vitro fertilization (IVF), also known as mitochondrial replacement or transfer.
• Three-parent IVF uses genetic material from three individuals to create a child, enabling women with mitochondrial disease to have genetically related offspring.
• This technology has raised significant ethical concerns, including safety, exploitation of egg donors, and objections to altering traditional procreation.

Purpose of the Study:

• To evaluate the ethical and social-policy implications of three-parent IVF.
• To assess whether three-parent IVF possesses sufficient social value to justify public research investment.
• To critically examine claims that three-parent IVF will eradicate mitochondrial disease and save lives.

Main Methods:

• Analysis of the IOM report and ethical considerations surrounding three-parent IVF.
• Examination of the social value argument against public investment in the technology.
• Distinction between creating healthy lives and eradicating disease.

Main Results:

• The IOM endorses clinical trials for three-parent IVF but overlooks a critical objection: its lack of social value for public funding.
• Three-parent IVF does not meet a plausible social value standard for public research investment.
• The technology's claims of eradicating mitochondrial disease and saving lives are exaggerated; it can create healthy lives but not eliminate the disease.

Conclusions:

• Public investment in three-parent IVF is ethically questionable due to its insufficient social value.
• Focusing on three-parent IVF represents an opportunity cost, diverting resources from treatments benefiting current mitochondrial disease sufferers.
• A moral distinction exists between creating healthy lives and eradicating a disease, impacting the ethical justification for public funding.